Liver disease-associated biomarkers and methods of use thereof
A technology for biomarkers and liver diseases, applied in the field of biomarkers
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0273] Patient Population for Example 1 Study
[0274] A total of 504 patients diagnosed with liver fibrosis and cirrhosis with an age distribution of 15 were recruited from April 2013 to December 2013 in Shuguang Hospital (Shanghai, China) and Xiamen Traditional Chinese Medicine Hospital (Xiamen, China) affiliated to Shanghai University of Traditional Chinese Medicine. -75 years old. According to the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China" (Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Hepatology, Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association) and "Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China" (2005)" (Engl 2007; 120:2159-73), the patient was clinically diagnosed with liver fibrosis or cirrhosis and infected with chronic hepatitis B. All patients were clinically stable at the time of evaluation. Exclusion criteria include...
Embodiment 2
[0283] Example 2 Liver Biopsy
[0284] Except for patients with liver disease diagnosed with decompensated cirrhosis, the remaining patients with liver disease underwent ultrasound-guided liver biopsy within 1 week of enrollment. Biopsy specimens were fixed with 10% formalin, routinely embedded in paraffin, and histological sections were processed with hematoxylin eosin and eosin and Masson staining. Diagnosis requires a liver biopsy with a minimum length of at least 1.5 cm and at least 6 portal tracts. Histological grading of necrotizing inflammation (G0 to G4) and liver Grading of Fibrosis (S0 to S4). All sections were independently and blindly assessed by three pathologists at Fudan University in Shanghai, China, and observations were processed by the Kappa Concordance Test.
Embodiment 3
[0285] Example 3 Serum sample collection
[0286]Hematology and general biochemical assays were measured using an LH750 hematology analyzer and a Synchron DXC800 clinical system (Beckman Coulter, USA) according to the manufacturer's protocol. Serum hyaluronic acid (HA) and laminin (LN) concentrations were measured with a chemiluminescence immunoassay analyzer (CLIA) system (LUMO, Shinova Systems, Shanghai, China). Coagulation function was measured using an automatic coagulation analyzer (STAGO Compact, Diagnostica Stago, France). Serum HBV-DNA levels were detected using a real-time polymerase chain reaction (PCR) system (LightCycler, 480, Roche, USA).
PUM
| Property | Measurement | Unit |
|---|---|---|
| pore size | aaaaa | aaaaa |
| Sensitivity | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More 


